Plakoridine A



Compound IDCDAMM01209
Common namePlakoridine A
IUPAC namemethyl 4-hydroxy-1-[2-(4-hydroxyphenyl)ethyl]-5-(2-oxooctadecylidene)-2-propylpyrrolidine-3-carboxylate
Molecular formulaC35H57NO5

Experimental data

Retention time16.01
Adduct[M+H]+
Actual mz572.434
Theoretical mz572.431
Error4.93
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.6054

Identifiers and class information

Inchi keyULFKEEJTLUNSEY-UTTGQTJXNA-N
SmilesO=C(C=C1N(CCC2=CC=C(O)C=C2)C(CCC)C(C(=O)OC)C1O)CCCCCCCCCCCCCCCC
SuperclassBenzenoids
ClassBenzene and substituted derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)6
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)25
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)571.839
Computed dipole moment(dipole)4.954
Total solvent accessible surface area (SASA)1015.61
Hydrophobic component of SASA (FOSA)723.094
Hydrophilic component of SASA (FISA)153.531
Pie component of the SASA (PISA)138.988
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1986.75
Number of hydrogen bond donors (donorHB)1
Number of hydrogen bond acceptors (accptHB)6.5
Free energy of solvation of dipole (dip^2/V)0.0123535
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0064001
Globularity descriptor (glob)0.752546
Predicted polarizability in cubic angstroms (QPpolrz)58.631
Predicted hexadecane/gas partition coefficient (QPlogPC16)19.184
Predicted octanol/gas partition coefficient (QPlogPoct)24.043
Predicted water/gas partition coefficient (QPlogPw)6.505
Predicted octanol/water partition coefficient (QPlogPo/w)7.648
Predicted aqueous solubility (QPlogS)-7.008
Conformation-independent predicted aqueous solubility (CIQPlogS)-7.757
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.925
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)86.47
Predicted brain/blood partition coefficient (QPlogBB)-2.352
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)38.825
Predicted skin permeability, log Kp (QPlogKp)-3.522
PM3 calculated ionization potential (IP(ev))8.994
PM3 calculated electron affinity (EA(eV))-0.032
Number of likely metabolic reactions (#metab)8
Prediction of binding to human serum albumin (QPlogKhsa)1.678
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)80.477
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)105.176
Number of nitrogen and oxygen atoms (#NandO)6
Number of violations of Lipinski’s rule of five (RuleOfFive)2
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P21554CNR1Cannabinoid receptor 1 (by homology)T76685SEA
P42261GRIA1Glutamate receptor ionotropic, AMPA 1T33584SEA
Q8NER1TRPV1Vanilloid receptorT83193SEA
P06746POLBDNA polymerase beta (by homology)T06958SwissTargetPrediction and SEA
P10827THRAThyroid hormone receptor alphaT79591SEA
P10828THRBThyroid hormone receptor beta-1T98933SEA
P43116PTGER2Prostanoid EP2 receptorT38529SEA
P49841GSK3BGlycogen synthase kinase-3 betaT70977SEA
P34972CNR2Cannabinoid receptor 2T37693SEA
P35408PTGER4Prostanoid EP4 receptorT18876SEA
Q9NRA0SPHK2Sphingosine kinase 2T31989SEA
Q9UBY5LPAR3Lysophosphatidic acid receptor Edg-7T95923SEA
Q9UJM8HAO1Hydroxyacid oxidase 1T63170SEA
O60603TLR2Toll-like receptor 2T82078SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T76685DI0031Anorexia nervosa[ICD-11: 6B80]P21554CNR1
T76685DI0214Insomnia[ICD-11: 7A00-7A0Z]P21554CNR1
T76685DI0308Obesity[ICD-11: 5B80-5B81]P21554CNR1
T33584DI0298Neuropathy[ICD-11: 8C0Z]P42261GRIA1
T83193DI0163General pain disorder[ICD-11: 8E43]Q8NER1TRPV1
T06958DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P06746POLB
T79591DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]P10827THRA
T79591DI0197Hypo-thyroidism[ICD-11: 5A00]P10827THRA
T98933DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]P10828THRB
T38529DI0003Abortion[ICD-11: JA00]P43116PTGER2
T38529DI0102Coronary atherosclerosis[ICD-11: BA52]P43116PTGER2
T38529DI0121Diabetic foot ulcer[ICD-11: BD54]P43116PTGER2
T38529DI0166Glaucoma[ICD-11: 9C61]P43116PTGER2
T38529DI0356Pulmonary hypertension[ICD-11: BB01]P43116PTGER2
T38529DI0378Sexual dysfunction[ICD-11: HA00-HA01]P43116PTGER2
T38529DI0413Transplant rejection[ICD-11: NE84]P43116PTGER2
T70977DI0288Myotonic disorder[ICD-11: 8C71]P49841GSK3B
T37693DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P34972CNR2
T37693DI0214Insomnia[ICD-11: 7A00-7A0Z]P34972CNR2
T18876DI0037Asthma[ICD-11: CA23]P35408PTGER4
T18876DI0175Heart failure[ICD-11: BD10-BD1Z]P35408PTGER4
T18876DI0264Migraine[ICD-11: 8A80]P35408PTGER4
T18876DI0303Non-small-cell lung cancer[ICD-11: 2C25]P35408PTGER4
T18876DI0324Pain[ICD-11: MG30-MG3Z]P35408PTGER4
T18876DI0360Rectum cancer[ICD-11: 2B92]P35408PTGER4
T18876DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P35408PTGER4
T18876DI0414Transplanted organ/tissue[ICD-11: QB63]P35408PTGER4
T31989DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]Q9NRA0SPHK2
T95923DI0146Fibrosis[ICD-11: GA14-GC01]Q9UBY5LPAR3
T95923DI0399Systemic sclerosis[ICD-11: 4A42]Q9UBY5LPAR3
T63170DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]Q9UJM8HAO1
T82078DI0346Prostate cancer[ICD-11: 2C82]O60603TLR2

Copyright © 2025